Systemic Mastocytosis - Pipeline Review, H2 2019

Systemic Mastocytosis - Pipeline Review, H2 2019

Systemic Mastocytosis - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Mastocytosis - Pipeline Review, H2 2019, provides an overview of the Systemic Mastocytosis (Gastrointestinal) pipeline landscape.

Systemic mastocytosis is a disorder where mast cells are abnormally increased in multiple organs including the bone marrow. Symptoms include shortness of breath, low blood pressure, hives and swelling, itching, diarrhea, headache, flushing and musculoskeletal pain. Treatment includes antihistamines and more aggressive forms of Systemic mastocytosis require interferon or chemotherapeutic agents.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Systemic Mastocytosis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Systemic Mastocytosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Systemic Mastocytosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Systemic Mastocytosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I and Preclinical stages are 1, 4, 2 and 2 respectively.

Systemic Mastocytosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Mastocytosis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Systemic Mastocytosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Systemic Mastocytosis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Systemic Mastocytosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Mastocytosis (Gastrointestinal)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Systemic Mastocytosis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Systemic Mastocytosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Systemic Mastocytosis - Overview
Systemic Mastocytosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Systemic Mastocytosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Systemic Mastocytosis - Companies Involved in Therapeutics Development
AB Science SA
Allakos Inc
Arog Pharmaceuticals Inc
Blueprint Medicines Corp
Bristol-Myers Squibb Co
Deciphera Pharmaceuticals Inc
Seattle Genetics Inc
Stemline Therapeutics Inc
Systemic Mastocytosis - Drug Profiles
AK-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
avapritinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLU-263 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brentuximab vedotin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
crenolanib besylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dasatinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
masitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ripretinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tagraxofusp - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Systemic Mastocytosis - Dormant Projects
Systemic Mastocytosis - Discontinued Products
Systemic Mastocytosis - Product Development Milestones
Featured News & Press Releases
Nov 25, 2019: AB Science provides the summary of webcast with Key opinion leaders on Indolent Systemic Mastocytosis
Nov 06, 2019: Blueprint Medicines to present initial data from phase 2 PIONEER trial of Avapritinib in patients with Indolent Systemic Mastocytosis at 61st ASH Annual Meeting and Exposition
Nov 04, 2019: AB Science will host a live webcast on indolent systemic mastocytosis on November 20, 2019
Oct 24, 2019: AB Science granted authorization to initiate phase 3 confirmatory study of Masitinib in indolent systemic mastocytosis
Aug 12, 2019: AB Science to present at two upcoming conferences in September 2019
Aug 05, 2019: AB Science provides an update on its masitinib clinical program
Jun 15, 2019: Blueprint Medicines presents updated EXPLORER trial data for Avapritinib in patients with systemic mastocytosis at 24th EHA Congress
Jun 04, 2019: AB Science is providing a summary of the web conference held on 4 June 2019
May 16, 2019: Blueprint Medicines announces data presentations at ASCO and EHA meetings from registration-enabling clinical trials of Avapritinib across multiple patient populations
Mar 27, 2019: Blueprint Medicines announces updates on regulatory submission plans and recent clinical progress of Avapritinib
Feb 19, 2019: Allakos announces positive phase 1 results with AK002 in Indolent Systemic Mastocytosis
Dec 02, 2018: Blueprint Medicines announces updated results from ongoing EXPLORER clinical trial of Avapritinib demonstrating broad clinical activity and significant symptom reductions in patients with systemic mastocytosis
Jun 15, 2018: Blueprint Medicines Announces Updated Data from Ongoing Phase 1 EXPLORER Clinical Trial of Avapritinib in Patients with Advanced Systemic Mastocytosis Showing Profound and Durable Clinical Activity
May 17, 2018: Blueprint Medicines Announces Data Presentations at Upcoming ASCO and EHA Meetings Supporting Plans for Rapid Development of Avapritinib in Patients with Gastrointestinal Stromal Tumors and Systemic Mastocytosis
Dec 10, 2017: Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of Avapritinib (BLU-285) in Patients with Advanced Systemic Mastocytosis Showing Evidence of Strong Clinical Activity
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Systemic Mastocytosis, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Systemic Mastocytosis - Pipeline by AB Science SA, H2 2019
Systemic Mastocytosis - Pipeline by Allakos Inc, H2 2019
Systemic Mastocytosis - Pipeline by Arog Pharmaceuticals Inc, H2 2019
Systemic Mastocytosis - Pipeline by Blueprint Medicines Corp, H2 2019
Systemic Mastocytosis - Pipeline by Bristol-Myers Squibb Co, H2 2019
Systemic Mastocytosis - Pipeline by Deciphera Pharmaceuticals Inc, H2 2019
Systemic Mastocytosis - Pipeline by Seattle Genetics Inc, H2 2019
Systemic Mastocytosis - Pipeline by Stemline Therapeutics Inc, H2 2019
Systemic Mastocytosis - Dormant Projects, H2 2019
Systemic Mastocytosis - Discontinued Products, H2 2019
List of Figures
Number of Products under Development for Systemic Mastocytosis, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook